Drugs in ATC Class B06AC

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B06 - OTHER HEMATOLOGICAL AGENTS

Up to B06A - OTHER HEMATOLOGICAL AGENTS

Drugs in ATC Class: B06AC - Drugs used in hereditary angioedema

Tradename	Generic Name
FIRAZYR	icatibant acetate
ICATIBANT ACETATE	icatibant acetate
ORLADEYO	berotralstat dihydrochloride
EKTERLY	sebetralstat
DAWNZERA (AUTOINJECTOR)	donidalorsen sodium

ATC Class B06AC (Hereditary Angioedema): Market Dynamics and Patent Landscape

Last updated: April 25, 2026

What is B06AC and which drugs define the market?

ATC Class B06AC covers drugs used in hereditary angioedema (HAE). Market value is driven by branded, mechanism-specific therapies that reduce attack frequency (long-term prophylaxis) and by on-demand agents that stop acute attacks.

In practice, the B06AC market clusters by therapeutic modality:

• C1-inhibitor replacement (human plasma-derived C1-INH or recombinant C1-INH)
• Bradykinin pathway inhibitors (notably bradykinin B2 receptor antagonism)
• Kallikrein inhibition (plasma kallikrein inhibitors)
• Genetic pathway therapies (gene-targeting programs are emerging but are not yet the dominant commercial base in B06AC)

Core commercial products commonly associated with HAE therapy (and widely referenced in payer formularies under B06AC) include:

• C1-inhibitor concentrates
• Icatibant
• Ecallantide (market access varies by country)
• Lanadelumab (kallikrein inhibitor)
• Berotralstat (oral kallikrein inhibitor)

How does the HAE treatment pathway shape market dynamics?

HAE management splits into two commercial engines:

1) Long-term prophylaxis (LTP)

LTP drives recurring revenue because patients remain on therapy for years. Product fit depends on:

• Dosing frequency (subcutaneous vs oral vs infusion)
• Ability to reduce attacks (measured in attack rate reductions)
• Safety and discontinuation outcomes
• Administrative burden and reimbursement criteria

This segment also absorbs competitive pressure from:

• Lower-dose maintenance strategies
• Oral or lower-frequency regimens
• Support programs that reduce discontinuation

2) On-demand treatment (ODT)

ODT drives acute-use demand. ODT volume is smaller than LTP value in many markets, but it is strategically important because it:

• Maintains brand presence during episodes
• Facilitates switching: patients can trial ODT before committing to LTP

ODT competition depends on:

• Onset time and home-use usability
• Self-administration eligibility and training requirements
• Cost-effectiveness under national guidelines

What pricing and access dynamics matter most?

Across EU and comparable high-income markets, access is typically governed by:

• Clinical severity (attack frequency, history of laryngeal attacks)
• Response to prophylaxis
• Eligibility for home treatment
• Step therapy and prior authorization protocols

Pricing pressure tends to emerge from:

• Loss of exclusivity for biologics and small molecules in this class
• Biosimilar/bio-comparable competition for C1-inhibitor concentrates where regulatory pathways allow it
• Therapy sequencing that shifts patients to newer mechanisms when payers refresh formulary rules

The market tends to reward:

• Therapies that convert acute-treatment patients to LTP
• Patient support models that improve persistence
• Country-specific contracting (tenders, outcome-based agreements)

What does the patent landscape look like for B06AC?

The B06AC patent landscape is dominated by:

• Composition-of-matter patents for small molecules (e.g., bradykinin pathway and kallikrein inhibitors)
• Formulation and method-of-use patents (dosing regimens, route specificity, prophylaxis vs on-demand indications)
• Biologics platform patents for recombinant proteins and their manufacturing processes (for C1-INH products where relevant)
• Second-generation patents targeting:
  • Lower frequency dosing
  • Pediatric regimens
  • Improved stability and administration
  • Updated attack-frequency endpoints

In this class, patent “activity” often concentrates in three layers:

1. Base drug (core MoA composition or biologic)
2. Next dosing (reduced frequency, extended half-life, adjusted maintenance dose)
3. Indication breadth (HAE subsets, prophylaxis timing, special populations)

Key structural features

• Small molecules: composition-of-matter plus multiple patent families covering dosing and new patient sets.
• Biologics: a smaller set of “clean” exclusivity expirations, but manufacturing and formulation patents can extend commercial leverage.
• Expanded regimens: method patents remain a dominant tool even after base exclusivity ends, especially for payers focused on regimen-level evidence.

Which companies anchor the exclusivity profile in HAE?

Commercial leadership and patenting concentration commonly centers on major global innovators with extensive enforcement histories in HAE.

In practice, HAE patent landscapes are most actively litigated and negotiated around:

• kallikrein inhibition products
• bradykinin receptor antagonism
• C1-inhibitor replacement platforms

This matters because most competitive entry routes depend on:

• patent expiry timing
• successful carving of protected methods (dosing/indications)
• ability to demonstrate bioequivalence/clinical equivalence (for smaller molecule generics) or comparability (for biologics)

Where do patent expirations typically cluster?

For B06AC, expirations tend to cluster around:

• mid-to-late 2020s for several small-molecule baselines (depending on the specific patent priority dates and jurisdictional term extensions)
• early 2030s for biologic-related families and later-life dosing innovations

Commercial impact comes from:

• how many jurisdictions share the same priority date
• whether pediatric extensions and regulatory exclusivity shift the effective earliest generic entry date
• enforcement success against method-of-use claims

How do patent expirations translate into market entry risk?

Generic and biosimilar timelines in HAE face two high-friction points:

1) Method-of-use protection

Even when a composition-of-matter claim falls away, prophylaxis or regimen-specific claims can keep market exclusivity meaningful. Common protected elements include:

• prophylaxis start criteria
• dose adjustment rules
• dosing interval definitions

2) Evidence and payer acceptance

If generic entry is legally possible but requires new clinical evidence for payers, adoption slows. That preserves revenue for branded products through:

• tender negotiations
• health system formulary updates
• clinician preference based on patient outcome history

What is the competitive patent-driven strategy post-expiry?

Incumbents typically defend commercial position through:

• continued marketing of the most effective regimen (often with lower attack rates)
• contracting aligned with patient persistence outcomes
• launching next-generation dosing (e.g., extended-interval prophylaxis or new subpopulation labels)

Entrants typically target:

• faster legal entry where method-of-use claims are narrow
• court-friendly positions that permit a “carve-out” to launch on non-protected indications or regimens (where applicable)
• pricing strategies aimed at tender entry rather than broad immediate uptake

What are the main patent “attack surfaces” for challengers?

For B06AC, generic or biosimilar challengers typically focus on:

• whether claims cover route (subcutaneous vs intravenous vs oral)
• whether claims cover dose and interval
• whether claims are tethered to specific endpoints or patient subgroups (e.g., pediatric dosing)
• whether regulatory exclusivity blocks approval or marketing, even if patents are weak

How does the landscape differ between biologics and small molecules in B06AC?

C1-inhibitor concentrates

• Patent families often include manufacturing, stabilization, and purity.
• Commercial entry is complicated by process and comparability expectations.
• The market reacts slower because clinicians and payers value predictable lot-to-lot response.

Kallikrein inhibitors and bradykinin-targeting agents

• Chemical synthesis and oral/subcutaneous formulations are more amenable to generic development.
• Method-of-use and dosing regimen patents remain a primary barrier.
• Market entry is typically faster when the main composition claims expire cleanly across major jurisdictions.

What is the practical investment and R&D implication of B06AC patent dynamics?

For R&D and investment, the class rewards:

• mechanistic differentiation that can secure new method-of-use and patient subgroup labels
• dosing optimization that creates new patent-protected regimens
• strong evidence packages that support payer access after legal entry by competitors

For entrants, success often depends on:

• navigating dosing and method-of-use claim scope
• securing early payer acceptance through economic models that match expected attack reduction
• avoiding launch delays tied to tender cycles

Market outlook: where demand growth is most likely to come from

Demand growth in HAE is typically driven by:

• expanding diagnosis rates
• increasing home treatment eligibility
• more prophylaxis adoption as evidence matures
• new patient subsets (pediatric expansion, pregnancy-related pathways)

Patent events can reshape growth by shifting patients between prophylaxis and acute-treatment use based on:

• availability of lower-cost options
• continued efficacy perceptions
• guideline updates tied to clinical trial outcomes

---

Key Takeaways

• B06AC market dynamics are built on two recurring engines: long-term prophylaxis and on-demand treatment, with LTP typically carrying the biggest commercial weight.
• Patent leverage in HAE is less about a single “base” compound and more about method-of-use and dosing regimen protection that can outlast composition-of-matter expirations.
• Competition timing depends on jurisdictional patent term calculations, regulatory exclusivity, and enforcement outcomes, not just on priority dates.
• Strategic winners are those with either (1) strong label expansion and regimen IP or (2) clean launch positions after method-of-use carve-outs.
• Clinical and payer adoption can delay the economic impact of legal entry, preserving branded revenue beyond headline expirations.

FAQs

1) What drives revenue in B06AC most consistently?
Long-term prophylaxis persistence, driven by dosing convenience, attack reduction outcomes, and reimbursement stability.

2) Why do patent expirations not automatically trigger rapid erosion?
Because method-of-use and dosing regimen patents frequently remain enforceable, and payer adoption cycles slow uptake even when legal barriers fall.

3) Which IP categories matter most for challengers in HAE?
Dosing interval and prophylaxis method claims, plus any route-specific restrictions and regimen-linked definitions.

4) Are biologics or small molecules more time-sensitive in this class?
Both are, but small molecules often face faster generic entry routes once composition claims weaken, while biologic competition is slower due to comparability and process constraints.

5) What is the clearest R&D strategy to extend commercial life in B06AC?
Develop and patent next-generation regimens that deliver extended dosing intervals, new patient subgroup labels, or refined prophylaxis criteria.

---

References

[1] European Medicines Agency (EMA). ATC classification: B06AC. EMA website.
[2] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: B06AC. WHOCC.
[3] FDA. Orange Book (where applicable for marketed products in hereditary angioedema). U.S. FDA.
[4] GlobalDossier / PATENTSCOPE public records for relevant HAE active ingredients and family members (by jurisdiction and priority date). WIPO.